Michael Narachi, President and CEO at Orexigen Therapeutics, Inc. (OREX), sold 150,000 shares at $6.66 ($1.0M) on 2012-07-12, disclosed to the SEC on 2012-07-13.
Scheduled sale ($1.0M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.66 | 2,900 | $19K | 1.9% |
| 2 | $6.70 | 147,100 | $986K | 98.1% |
| Total | $6.70 avg | 150,000 | $1.0M | 100% |
| Filing → |
| OREX | SELL | 2012-07-19 | $1.1M | — | Filing → |
| OREX | SELL | 2012-06-29 | $1.3M | — | Filing → |
| AMAG | BUY | 2012-05-29 | $27K | — | Filing → |